Strip the spin and the gene-editing ownership story gets more complicated. Most gene-editing companies pitch a clean estate — "our targets, our edits, our IP." The fact that undercuts the tidy version is upstream: foundational patents on the editing enzymes themselves, held largely by research institutes. The Broad Institute's US12644111B2, "CRISPR enzymes and systems" (issued June 2, 2026, inventors including Zhang), is a current example of that foundational layer (CPC C12N 9/22, nucleases; C12N 15/111, nucleic-acid systems).
Let me steelman the clean story first, because it is not nonsense. A company really can own its target-specific edits, its delivery, and its clinical data outright — those are genuine, bankable assets, as this desk has covered. The pitch is not a lie. It is just incomplete, because owning the application does not mean owning the tool.
Now the deflationary read. The enzymes and systems at the base of CRISPR editing are claimed in foundational patents that most developers did not file. To practice their own application, companies frequently must license — or design around — that foundational IP. That licensing obligation is a royalty tier, a negotiating dependency, and in some cases a litigation risk that sits above the company's own estate. A deal that ignores it is mispriced.
What the foundational grant does not mean: that any one institute controls all of CRISPR, or that every developer infringes. The foundational landscape is contested and fragmented across institutes and enzyme classes, and many companies hold valid licenses or use non-foundational tools. The point is not that the upstream IP is fatal — it is that it exists, and a clean ownership slide that omits it is selling a simplification.
The editor's standard, applied: before crediting a gene-editing company's ownership story, ask what foundational enzyme IP its platform relies on and whether that is owned, licensed, or unresolved. The Broad's enzyme grant is one marker of the layer every such deal must navigate. The bull case can survive the question — but the analysis that skips it is not analysis, it is the press release.